New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
11:02 EDTGILDU.K.'s NICE asks Gilead for additional information on Sovaldi
The U.K.'s National Institute for Health and Care Excellence, a healthcare guidance body, is asking Gilead Sciences for more information on its Sovaldi drug for the treatment of chronic hepatitis C in draft recommendations published today. Professor Carole Longson, Director of the NICE Centre for Health Technology Evaluation, said: “The available evidence shows that sofosbuvir is an effective treatment for chronic hepatitis C in certain patients. However, evidence is lacking for some subgroups of patients with chronic hepatitis C, and there are also substantial uncertainties in the evidence base presented by the manufacturer. The Committee has therefore requested further information from the manufacturer before it can decide whether sofosbuvir is a cost-effective use of NHS resources.” NICE noted that this is draft guidance and that it has not yet issued final guidance to the NHS. The closing date for comments on the draft guidance is July 4. Reference Link
News For GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent GILD news | >>
April 27, 2015
07:38 EDTGILDGilead May weekly volatility elevated into Q1 and outlook
Subscribe for More Information
April 26, 2015
14:56 EDTGILDGilead reports 'high cure rates' for Sovaldi in genotype 2-5 hep C patients
Subscribe for More Information
April 24, 2015
09:37 EDTGILDActive equity options trading on open
Subscribe for More Information
08:33 EDTGILDGilead May weekly volatility elevated into Q1 and outlook
Subscribe for More Information
April 23, 2015
16:01 EDTGILDOptions Update; April 23, 2015
Subscribe for More Information
07:59 EDTGILDMylan launches generic sofosbuvir tablets in India
Subscribe for More Information
05:19 EDTGILDGilead Harvoni, Sovaldi demonstrate efficacy, safety
Gilead Sciences announced results from several Phase 2 clinical studies evaluating investigational uses of Harvoni and other Sovaldi-based regimens for the treatment of chronic hepatitis C virus, or HCV, infection in patients with advanced liver disease, including patients with decompensated cirrhosis, patients with fibrosing cholestatic hepatitis C and patients with portal hypertension. In SOLAR-2, 328 genotype 1 or 4 HCV patients with decompensated liver disease before liver transplantation or recurrent HCV infection following liver transplantation were randomized to receive either 12 or 24 weeks of Harvoni plus ribavirin. Ten patients were excluded from the analysis because of transplantation or because they were pre-transplantation, but not decompensated; an additional 27 of these patients have not yet reached post-treatment week 12. The most common adverse events were fatigue, anemia, nausea and headache. Overall, six patients discontinued treatment due to adverse events, five of whom had decompensated cirrhosis.
05:16 EDTGILDGilead data supports ongoing trials evaluating shortened course of therapy
Subscribe for More Information
April 22, 2015
07:07 EDTGILDEuropean Association for the Study of the Liver to hold annual meeting
50th Annual Meeting of EASL will be held in Vienna, Austria on April 22-26.
April 21, 2015
16:00 EDTGILDOptions Update; April 21, 2015
iPath S&P 500 VIX Short-Term Futures down 1c to 21.53 Option volume leaders: AAPL TSLA TWTR GILD FB PBR AMZN C KMI KO VZ MCD according to Track Data.
13:34 EDTGILDGilead paying premium to buy Vertex not warranted right now, says Maxim
After Bernstein suggested in a note to investors earlier that Gilead (GILD) should buy Vertex (VRTX), Maxim responded in its own note that it does not believe paying a premium to buy Vertex makes sense before the company has data showing efficacy for Kalydeco in heterozygotes. Maxim keeps a Hold rating and $121 price target on Vertex shares.
12:33 EDTGILDOn The Fly: Top stock stories at midday
Subscribe for More Information
12:21 EDTGILDVertex rises after Bernstein suggests Gilead should pursue takeover
Subscribe for More Information
10:00 EDTGILDGilead spikes higher, levels to watch
Subscribe for More Information
09:37 EDTGILDActive equity options trading on open
Subscribe for More Information
08:14 EDTGILDGilead should buy Vertex, says Bernstein
Subscribe for More Information
06:58 EDTGILDGilead May weekly volatility elevated into Q1 and outlook
Subscribe for More Information
April 20, 2015
09:36 EDTGILDActive equity options trading on open
Subscribe for More Information
07:20 EDTGILDAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information
April 15, 2015
16:01 EDTGILDOptions Update; April 15, 2015
iPath S&P 500 VIX Short-Term Futures down 49c to 21.90. Option volume leaders: AAPL NFLX C PBR KMI RIG MCP TWTR GILD BAC according to Track Data.
1 | 2 | all recent GILD news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use